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The safety of chemotherapy for patients with systemic sclerosis (SSc) is 
unclear, and there are few published reports documenting the side effects of 
chemotherapy in patients with this condition. Here, we report the case of a 
patient with SSc who developed severe digital ischemia during combination 
gemcitabine/S-1 chemotherapy for pancreatic cancer. In spite of aggressive 
treatment, the digital ischemia progressively worsened and gangrenous 
changes developed in multiple fingers and toes. In this patient, the SSc had 
been well controlled, with no digital ischemic symptoms for the previous 6 
years, so this progressive clinical course in spite of aggressive treatment 
strongly suggests that the chemotherapy triggered or aggravated the digital 
necrosis. To the best of our knowledge, this is only the third reported case of 
a patient with SSc developing digital necrosis after gemcitabine-based 
chemotherapy. The incidence of digital necrosis during chemotherapy in 
patients with SSc is unknown, and the mechanism by which it occurs is 
unclear, but the three reports published to date, including the present case, 
suggest that physicians should be very cautious about administering 
gemcitabine-based chemotherapy to patients with SSc. Any resulting digital 
ischemia might be refractory to treatment and worsen progressively, even if 
chemotherapy is withdrawn in the early stages of digital ischemia. 
 
Mini-abstract 
A patient with systemic sclerosis who underwent gemcitabine/S-1 
chemotherapy developed progressive digital ischemia after a 6-year period 
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without such symptoms, strongly suggesting that the chemotherapy caused 
the ischemia. 
 





Patients with systemic sclerosis (SSc) are at increased risk of cancer [1], so 
it seems likely that a not inconsiderable number of SSc patients require and 
receive chemotherapy in daily clinical practice. Over 90% of SSc patients 
experience Raynaud’s phenomenon, which, in a small number of cases, 
progresses to digital necrosis [2, 3]. Anti-cancer drugs have the potential to 
cause vascular toxicity, including digital necrosis [4-9], so patients with SSc 
may be more susceptible than others to vascular toxicity arising from 
treatment with anti-cancer drugs. However, the risks for SSc patients of the 
vascular toxicity associated with chemotherapy are poorly understood.  
Here, we report a patient with SSc who developed digital ischemia after 
gemcitabine/S-1 combination therapy, which became gangrenous in spite of 





A 69-year-old man developed advanced pancreatic cancer with peritoneal 
dissemination in 2008. He had a history of SSc, which was diagnosed in 
1999 and had been well controlled without medication since 2002. He had 
experienced acute myocardial infarction at the age of 51, and had had 
diabetes mellitus for 16 years. He had given up smoking 19 years earlier, 
before which he had had a smoking habit of 22 packs/year. Although there 
had been no symptoms of digital ischemia over the past 6 years, we were 
reluctant to treat the pancreatic cancer with systemic chemotherapy 
because it might increase the risk of digital necrosis. We strongly cautioned 
the patient about this risk, but he was firm in his wish to receive 
chemotherapy treatment. 
Combination chemotherapy using gemcitabine (400 mg/m2, days 1 and 8) 
and S-1 (80 mg/day, days 1–14) every 3 weeks was started in December 2008. 
A low dose of gemcitabine was selected given the risk of digital necrosis. The 
patient’s pancreatic cancer was well controlled with chemotherapy and no 
significant toxicity was observed until June 2009, when he experienced 
Raynaud’s phenomenon. The patient had previously experienced Raynaud’s 
phenomenon, but not for the past 6 years. At this stage, we strongly 
recommended suspension of chemotherapy; however, the patient refused to 
discontinue the chemotherapy for fear of the pancreatic cancer progressing. 
The Raynaud’s phenomenon was treated with vasodilators, antiplatelet 
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drugs and prostaglandin; however, despite the treatment, ischemic changes 
became evident (Fig. 1A). In July 2009, chemotherapy was discontinued and 
the patient was hospitalized for treatment of the digital ischemia. Initially, 
he was treated with prostaglandin, vasodilators, antiplatelet drugs and 
antithrombin, but these treatments brought about no improvements. Next, 
bosentan hydrate was administered and a sympathetic nerve block was 
implemented, but again neither of these treatments yielded any 
improvement in the digital ischemia. The digital ischemia progressively 
worsened and in September 2009 gangrenous changes developed in multiple 
fingers and toes (Fig. 1B). Because the digital ischemia was not complicated 
with infection, amputation was not performed. The patient died in January 








To the best of our knowledge, this is only the third reported case in the 
English-language literature of an SSc patient developing digital necrosis 
after chemotherapy [5, 6] (Table 1). In all three cases, gemcitabine was 
included in the chemotherapy regimen, and digital necrosis developed 3, 16 
and 27 weeks after chemotherapy began, respectively. All three patients 
eventually developed gangrenous changes in spite of the best available 
treatment for the digital ischemia, whereas complete recovery from digital 
ischemia after chemotherapy has been reported for patients without SSc [6]. 
Gemcitabine is known to cause digital ischemia in patients without SSc, 
with the vascular toxicity thought to be due to its causing endothelial 
damage or a hypercoagulable state [5-7]. We could not find any reports in 
the literature documenting digital ischemia following S-1 treatment. In the 
present case it is not possible to conclude which agent played the greater 
role in the development of ischemia; determining whether gemcitabine is 
associated with a higher risk of vascular toxicity compared with other 
anti-cancer drugs in SSc patients requires further study. 
In the present case, we cannot rule out the possibility that factors other 
than chemotherapy were involved in the development of digital ischemia. 
The patient had a history of smoking and diabetes mellitus, both of which 
could potentially increase the risk of digital ischemia. However, considering 
that the patient had experienced no symptoms of digital ischemia over the 
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previous 6 years, and had undergone a progressive clinical course in spite of 
aggressive treatment, we strongly suspect that chemotherapy triggered or 
aggravated the digital ischemia in this patient.  
Vascular toxicity is a rare but serious side effect of chemotherapy [4-9]. The 
precise incidence is unknown, and the mechanism by which chemotherapy 
causes digital necrosis in patients with SSc remains unclear, but in the light 
of previous case studies, the present findings strongly suggest that 
physicians should be very cautious about administering chemotherapy, 
especially gemcitabine-based chemotherapy, to SSc patients. The resulting 
digital ischemia might be refractory to conventional treatment and worsen 
progressively, even if chemotherapy is withdrawn at an early stage in the 







1. Olesen AB, Sværke C, Farkas DK, Sørensen HT. Systemic sclerosis and 
the risk of cancer: A nationwide population based cohort study. Br J 
Dermatol 2010;163:800-6. 
 
2. Tiev KP, Diot E, Clerson P, Dupuis-Siméon F, Hachulla E, Hatron PY, et 
al. Clinical features of scleroderma patients with or without prior or 
current ischemic digital ulcers: post-hoc analysis of a nationwide 
multicenter cohort (ItinérAIR-Sclérodermie). J Rheumatol 
2009;36:1470-6. 
 
3. Kahaleh B. The microvascular endothelium in scleroderma. 
Rheumatology (Oxford) 2008;47 Suppl 5:v14-5.  
 
4. Shahab N, Haider S, Doll DC. Vascular toxicity of antineoplastic agents. 
Semin Oncol 2006;33:121-38. 
 
5. Holstein A, Bätge R, Egberts EH. Gemcitabine induced digital 
ischaemia and necrosis. Eur J Cancer Care 2010;19:408-9.  
 
6. Barceló R, López-Vivanco G, Mañé JM, Rubio I, Muñoz A, Fernández R. 
Distal ischemic changes related to combination chemotherapy with 
cisplatin and gemcitabine: description of four cases. Ann Oncol 
2000;11:1191-4. 
 
7. Vénat-Bouvet L, Ly K, Szelag JC, Martin J, Labourey JL, Genet D, 
et al. Thrombotic microangiopathy and digital necrosis: two 
unrecognized toxicities of gemcitabine. Anticancer Drugs 
2003;14:829-32. 
 
8. Cloese ME, Wigley FM. Digital necrosis related to carboplatin and 
gemcitabine therapy in systemic sclerosis. J Rheumatol 2003;30:1341-3.  
 
9. Marie I, Levesque H, Plissonnier D, Balguerie X, Cailleux N, Courtois H. 










Fig. 1 Progression of digital ischemia in a patient with systemic sclerosis, 
who was undergoing gemcitabine/S-1 combination chemotherapy for 
pancreatic cancer. (A) Digital ischemia at the time of hospitalization in July 
2009. (B) Worsening digital ischemia and development of gangrene in 













Table 1. Published case reports of digital necrosis following chemotherapy in 





Cloese et al.[8] Marie et al.[9] Present case 
Patient age 
(years) 
50 49 69 
Patient sex Female Female Male 
Primary 
disease 
































































†Time of onset after start of chemotherapy. 
 
